Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: January 27, 2023

Details for Patent: 8,110,574

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 8,110,574
Title:Derivatives of 4-aminopiperidine and their use as a medicament
Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula ##STR00001## in which R.sub.1, R.sub.2 and R.sub.3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
Inventor(s): Thurieau; Christophe (Paris, FR), Gonzalez; Jerome (Annemasse, JP), Moinet; Christophe (Montreal, CA)
Assignee: Ipsen Pharma S.A.S. (Boulogne-Billancourt, FR)
Application Number:12/946,504
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,110,574

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,110,574

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France99 15724Dec 14, 1999

International Family Members for US Patent 8,110,574

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034244 See Plans and Pricing
Austria 401308 See Plans and Pricing
Australia 2856001 See Plans and Pricing
Australia 779341 See Plans and Pricing
Canada 2394086 See Plans and Pricing
China 1207283 See Plans and Pricing
China 1409703 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.